Small-volume oral transmucosal dosage forms
First Claim
Patent Images
1. A dosage form for oral transmucosal administration to a subject, comprising:
- from about 0.25 micrograms to about 200 micrograms sufentanil, wherein said dosage form is bioadhesive and has a volume of less than 30 microliters or a mass of less than 30 mg wherein after administration of the dosage form to the subject, the dosage form provides a Tmax with a coefficient of variation less than 40%, wherein said Tmax is from about 19.8 minutes to about 60 minutes.
3 Assignments
0 Petitions
Accused Products
Abstract
Small-volume oral transmucosal dosage forms or NanoTabs® comprising a predetermined amount of a pharmaceutically active drug are provided. Exemplary applications include use of the NanoTabs® to administer a drug for the treatment of acute, post-operative or breakthrough pain.
318 Citations
16 Claims
-
1. A dosage form for oral transmucosal administration to a subject, comprising:
- from about 0.25 micrograms to about 200 micrograms sufentanil, wherein said dosage form is bioadhesive and has a volume of less than 30 microliters or a mass of less than 30 mg wherein after administration of the dosage form to the subject, the dosage form provides a Tmax with a coefficient of variation less than 40%, wherein said Tmax is from about 19.8 minutes to about 60 minutes.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
-
15. A dosage form for oral transmucosal administration to a subject, comprising:
- a bioadhesive dosage form of from about 0.25 micrograms to about 200 micrograms sufentanil with a volume of less than 30 microliters or a mass of less than 30 mg wherein the administration of the dosage form to the subject results in a dose-normalized Cmax of 2.72+/−
0.84 pg/mL per mcg of sufentanil dosed and a Tmax with a coefficient of variation less than 40%. - View Dependent Claims (16)
- a bioadhesive dosage form of from about 0.25 micrograms to about 200 micrograms sufentanil with a volume of less than 30 microliters or a mass of less than 30 mg wherein the administration of the dosage form to the subject results in a dose-normalized Cmax of 2.72+/−
Specification